Arnauld C. Verschuur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Arnauld C. Verschuur has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Albert H. Van Gennip
Laboratory of Genetic Metabolic Diseases, Divisions of Clinical Chemistry and Pediatrics, Academic Medical Centre, University of Amsterdam, Emma Kinderziekenhuis AMC, Amsterdam, The Netherlands
2 shared publicationsP.A. Voûte
Department of Pediatric Oncology, Division of Pediatrics, Academic Medical Centre, University of Amsterdam, Emma Kinderziekenhuis AMC, Amsterdam, The Netherlands
2 shared publicationsA Lelouch-Tubiana
22Department of Pathology, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75015 Paris, France
1 shared publicationA.B.P Van Kuilenburg
Laboratory of Genetic Metabolic Diseases, Divisions of Clinical Chemistry and Pediatrics, Academic Medical Centre, University of Amsterdam, Emma Kinderziekenhuis AMC, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands
1 shared publicationA.B.P. Van Kuilenburg
Laboratory of Genetic Metabolic Diseases, Division of Clinical Chemistry, Academic Medical Centre, University of Amsterdam, Emma Kinderziekenhuis AMC, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands
1 shared publicationA.H Van Gennip
Laboratory of Genetic Metabolic Diseases, Divisions of Clinical Chemistry and Pediatrics, Academic Medical Centre, University of Amsterdam, Emma Kinderziekenhuis AMC, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands
1 shared publication
Latest Publications
- 12 October 2006
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (2) , 399-401
Respiratory symptoms in a boy revealing Carney triad
The association of gastrointestinal stromal cell tumor (GIST), paraganglioma, and pulmonary chondroma is known as the Carney triad, occurring predominantly in young adult females. We present the case of a 14‐year‐old male with respiratory symptoms resulting in the diagnosis Carney triad. Pediatr Blood Cancer 2008;50:399–401.
- 12 October 2006
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (2) , 399-401
Respiratory symptoms in a boy revealing Carney triad
The association of gastrointestinal stromal cell tumor (GIST), paraganglioma, and pulmonary chondroma is known as the Carney triad, occurring predominantly in young adult females. We present the case of a 14‐year‐old male with respiratory symptoms resulting in the diagnosis Carney triad. Pediatr Blood Cancer 2008;50:399–401.
- Open Access
- 20 July 2004
- Published by Springer Nature in British Journal of Cancer
- Vol. 91 (3) , 425-429
Temozolomide in paediatric high-grade glioma: a key for combination therapy?
This report describes a single-centre study with temozolomide (TMZ) (200 mg m−2 day−1 × 5 per cycle of 28 days) in children with (recurrent) high-grade glioma. Magnetic resonance imaging was performed every two cycles. In all, 20 patients were treated between 1998 and 2001 after the UKCCSG/SFOP TMZ phase II trial. All patients had measurable disease. Totally, 15 patients had a relapse after surgery±radiotherapy±chemotherapy. Overall, five patients received TMZ after surgery or biopsy, awaiting radiotherapy. There were one clinically malignant grade II glioma, 11 grade III and eight grade IV gliomas. Seven tumours had oligodendroglial features. Mean age at start of TMZ was 12.0 years (range 3–20.5 years). In total, eight patients had >8 cycles (range 3–30). One VGPR (currently in CR after surgery), three PRs (with a PFS of 4, 4 and 11 months, respectively) and one MR (PFS 14 months) were observed. Three out of five responses occurred after >4 courses. The overall response rate was 20%. Median progression-free survival (PFS) was 2.0 months (range 3 weeks–34+ months). PFS rate was 20% after 6 months. Median overall survival (OS) was 10 months. Nine patients showed a clinical improvement. Three patients vomitted shortly after TMZ administration, eight patients (13 cycles) experienced grade III/IV thrombocytopenia, occurring predominantly during the fourth week of the first two cycles. Five patients experienced neutropenia, and three patients febrile neutropenia. TMZ is a well-tolerated ambulatory treatment for children with malignant glial tumours. This drug warrants further study in these highly chemoresistant tumours and should be studied either as upfront therapy or in combination therapy.
- 20 July 2004
- Published by Springer Nature in British Journal of Cancer
- Vol. 91 (3) , 425-429
Open AccessTemozolomide in paediatric high-grade glioma: a key for combination therapy?
This report describes a single-centre study with temozolomide (TMZ) (200 mg m−2 day−1 × 5 per cycle of 28 days) in children with (recurrent) high-grade glioma. Magnetic resonance imaging was performed every two cycles. In all, 20 patients were treated between 1998 and 2001 after the UKCCSG/SFOP TMZ phase II trial. All patients had measurable disease. Totally, 15 patients had a relapse after surgery±radiotherapy±chemotherapy. Overall, five patients received TMZ after surgery or biopsy, awaiting radiotherapy. There were one clinically malignant grade II glioma, 11 grade III and eight grade IV gliomas. Seven tumours had oligodendroglial features. Mean age at start of TMZ was 12.0 years (range 3–20.5 years). In total, eight patients had >8 cycles (range 3–30). One VGPR (currently in CR after surgery), three PRs (with a PFS of 4, 4 and 11 months, respectively) and one MR (PFS 14 months) were observed. Three out of five responses occurred after >4 courses. The overall response rate was 20%. Median progression-free survival (PFS) was 2.0 months (range 3 weeks–34+ months). PFS rate was 20% after 6 months. Median overall survival (OS) was 10 months. Nine patients showed a clinical improvement. Three patients vomitted shortly after TMZ administration, eight patients (13 cycles) experienced grade III/IV thrombocytopenia, occurring predominantly during the fourth week of the first two cycles. Five patients experienced neutropenia, and three patients febrile neutropenia. TMZ is a well-tolerated ambulatory treatment for children with malignant glial tumours. This drug warrants further study in these highly chemoresistant tumours and should be studied either as upfront therapy or in combination therapy.
- Open Access
- 22 January 2002
- Published by Wiley in International Journal of Cancer
- Vol. 98 (4) , 616-623
Cyclopentenyl cytosine increases the phosphorylation and incorporation into DNA of 1‐β‐D‐arabinofuranosyl cytosine in a human T‐lymphoblastic cell line
The cytotoxic effect of 1‐β‐D‐arabinofuranosyl cytosine (araC) depends on the intracellular phosphorylation into its active compound araCTP, on the degree of degradation of araCTP and on the incorporation of araCTP into DNA. Deoxycytidine triphosphate (dCTP) inhibits the phosphorylation of araC (by feedback inhibition of the enzyme deoxycytidine kinase) and the incorporation of araCTP into DNA (by competition for DNA polymerase). In a T‐lymphoblastic cell line, we studied whether the cytotoxicity of araC (2 nM–50 μM) could be enhanced by decreasing the concentration of dCTP, using the nucleoside‐analogue cyclopentenyl cytosine (CPEC), an inhibitor of the enzyme CTP synthetase. Preincubation of the cells with CPEC (100–1,600 nM) for 2 hr increased the concentrations of araCMP 1.6–9.5‐fold, which was significant for each concentration of CPEC used. The concentration of araCDP remained low, whereas the concentration of araCTP changed depending on the concentration of araC used. With 2–15 μM of araC and a preincubation with 400 nM of CPEC, the araCTP concentration increased by 4–15% (not significant), and the total amount of araC nucleotides increased significantly by 21–45%. When using a concentration of araC of 2 nM after a preincubation with CPEC of 100 nM, the concentration of araCMP increased by 60% (p = 0.015), whereas that of araCTP decreased by 10% (p = 0.008). This was compensated by an increase of 41% (p = 0.005) of araCTP incorporation into DNA, which represented 43% of all araC metabolites. Moreover, by performing pulse/chase experiments with 400 nM of CPEC and 2μM of araC, the retention of cytosolic araCTP and the incorporated amount of araCTP into DNA were increased by CPEC. The modulation by CPEC of araC metabolism was accompanied by a synergistic increase of araC‐induced apoptosis and by an additive effect on the araC‐induced growth inhibition.
- 22 January 2002
- Published by Wiley in International Journal of Cancer
- Vol. 98 (4) , 616-623
Open AccessCyclopentenyl cytosine increases the phosphorylation and incorporation into DNA of 1‐β‐D‐arabinofuranosyl cytosine in a human T‐lymphoblastic cell line
The cytotoxic effect of 1‐β‐D‐arabinofuranosyl cytosine (araC) depends on the intracellular phosphorylation into its active compound araCTP, on the degree of degradation of araCTP and on the incorporation of araCTP into DNA. Deoxycytidine triphosphate (dCTP) inhibits the phosphorylation of araC (by feedback inhibition of the enzyme deoxycytidine kinase) and the incorporation of araCTP into DNA (by competition for DNA polymerase). In a T‐lymphoblastic cell line, we studied whether the cytotoxicity of araC (2 nM–50 μM) could be enhanced by decreasing the concentration of dCTP, using the nucleoside‐analogue cyclopentenyl cytosine (CPEC), an inhibitor of the enzyme CTP synthetase. Preincubation of the cells with CPEC (100–1,600 nM) for 2 hr increased the concentrations of araCMP 1.6–9.5‐fold, which was significant for each concentration of CPEC used. The concentration of araCDP remained low, whereas the concentration of araCTP changed depending on the concentration of araC used. With 2–15 μM of araC and a preincubation with 400 nM of CPEC, the araCTP concentration increased by 4–15% (not significant), and the total amount of araC nucleotides increased significantly by 21–45%. When using a concentration of araC of 2 nM after a preincubation with CPEC of 100 nM, the concentration of araCMP increased by 60% (p = 0.015), whereas that of araCTP decreased by 10% (p = 0.008). This was compensated by an increase of 41% (p = 0.005) of araCTP incorporation into DNA, which represented 43% of all araC metabolites. Moreover, by performing pulse/chase experiments with 400 nM of CPEC and 2μM of araC, the retention of cytosolic araCTP and the incorporated amount of araCTP into DNA were increased by CPEC. The modulation by CPEC of araC metabolism was accompanied by a synergistic increase of araC‐induced apoptosis and by an additive effect on the araC‐induced growth inhibition.
- 28 August 2001
- Published by Elsevier in Leukemia Research
- Vol. 25 (10) , 891-900
Cyclopentenyl cytosine induces apoptosis and increases cytarabine-induced apoptosis in a T-lymphoblastic leukemic cell-line
- 28 August 2001
- Published by Elsevier in Leukemia Research
- Vol. 25 (10) , 891-900
Cyclopentenyl cytosine induces apoptosis and increases cytarabine-induced apoptosis in a T-lymphoblastic leukemic cell-line
- Open Access
- 1 July 2000
- Published by Wiley in British Journal of Haematology
- Vol. 110 (1) , 161-169
In vitro inhibition of cytidine triphosphate synthetase activity by cyclopentenyl cytosine in paediatric acute lymphocytic leukaemia
Cytidine triphosphate (CTP) synthetase is a key enzyme for the synthesis of cytosine (deoxy)ribonucleotides, catalysing the conversion of uridine triphosphate (UTP) into CTP, and has a high activity in several malignancies. In this preclinical study, the enzyme activity and mRNA expression of the enzyme and (deoxy)ribonucleotide concentrations were analysed in leukaemic cells of 57 children suffering from acute lymphocytic leukaemia (ALL). In addition, in vitro experiments were performed with the CTP synthetase inhibitor cyclopentenyl cytosine (CPEC). A significantly higher activity of CTP synthetase (6·5 ± 3·9 nmol CTP/mg/h) was detected in ALL cells than in lymphocytes of healthy controls (1·8 ± 0·9 nmol CTP/mg/h, P < 0·001) that was independent of white blood cell (WBC) count, blast percentage, age, gender or type of ALL. The enzyme activity was not correlated with the CTP synthetase mRNA expression. The activity of CTP synthetase in ALL cells compared with non‐malignant CD34+ bone marrow controls (5·6 ± 2·4 nmol CTP/mg/h) was not statistically different. In vitro treatment of ALL cells with CPEC induced a dose‐dependent decrease of the CTP concentration. The lowest concentration of CPEC (0·63 µm) induced a depletion of CTP of 41 ± 20% and a depletion of dCTP of 27 ± 21%. The degree of CTP depletion of ALL cells after treatment with CPEC was positively correlated with the activity of CTP synthetase. The inhibition of CTP synthetase in situ was confirmed by flux studies using radiolabelled uridine. From these results, it can be expected that CPEC has a cytostatic effect on lymphoblasts of children with ALL.
- 1 July 2000
- Published by Wiley in British Journal of Haematology
- Vol. 110 (1) , 161-169
Open AccessIn vitro inhibition of cytidine triphosphate synthetase activity by cyclopentenyl cytosine in paediatric acute lymphocytic leukaemia
Cytidine triphosphate (CTP) synthetase is a key enzyme for the synthesis of cytosine (deoxy)ribonucleotides, catalysing the conversion of uridine triphosphate (UTP) into CTP, and has a high activity in several malignancies. In this preclinical study, the enzyme activity and mRNA expression of the enzyme and (deoxy)ribonucleotide concentrations were analysed in leukaemic cells of 57 children suffering from acute lymphocytic leukaemia (ALL). In addition, in vitro experiments were performed with the CTP synthetase inhibitor cyclopentenyl cytosine (CPEC). A significantly higher activity of CTP synthetase (6·5 ± 3·9 nmol CTP/mg/h) was detected in ALL cells than in lymphocytes of healthy controls (1·8 ± 0·9 nmol CTP/mg/h, P < 0·001) that was independent of white blood cell (WBC) count, blast percentage, age, gender or type of ALL. The enzyme activity was not correlated with the CTP synthetase mRNA expression. The activity of CTP synthetase in ALL cells compared with non‐malignant CD34+ bone marrow controls (5·6 ± 2·4 nmol CTP/mg/h) was not statistically different. In vitro treatment of ALL cells with CPEC induced a dose‐dependent decrease of the CTP concentration. The lowest concentration of CPEC (0·63 µm) induced a depletion of CTP of 41 ± 20% and a depletion of dCTP of 27 ± 21%. The degree of CTP depletion of ALL cells after treatment with CPEC was positively correlated with the activity of CTP synthetase. The inhibition of CTP synthetase in situ was confirmed by flux studies using radiolabelled uridine. From these results, it can be expected that CPEC has a cytostatic effect on lymphoblasts of children with ALL.
- 1 March 2000
- Published by Elsevier in European Journal of Cancer
- Vol. 36 (5) , 627-635
Cyclopentenyl cytosine inhibits cytidine triphosphate synthetase in paediatric acute non-lymphocytic leukaemia
- 1 March 2000
- Published by Elsevier in European Journal of Cancer
- Vol. 36 (5) , 627-635
Cyclopentenyl cytosine inhibits cytidine triphosphate synthetase in paediatric acute non-lymphocytic leukaemia